The purpose of this investigation is to use antibody-directed liposomes containing cytotoxic agents to achieve specific in vitro destruction of leukemia cells in murine bone marrow prior to bone marrow transplantation. The model system will be the murine T-cell leukemia, AKR/J SL2, which can be implanted in congenic AKR/Cu mice, who differ only at the Thy 1 antigen. We have already shown effective and specific in vitro cell growth inhibition of SL2 leukemia cells by methotrexate-Gamma-aspartate encapsulated in liposomes conjugated with anti-Thy 1.1 antibody. Drug encapsulated in staphylococcal protein A-conjugated-liposomes (SPA-liposomes) is even more effective against the SL2 cells. The SPA-liposomes are 50-fold more effective against cells that have been pre-incubated with anti-Thy 1.1 than against SL2 cells incubated with non-specific antibody, and 144-fold more effective than free drug. Cell growth assays will be used to determine the optimal SPA-liposomes with regard to lipid composition, choice of drug, and choice of antibody or combinations of antibodies. The liposome efficacy will then be confirmed in a colony assay. The SPA-liposomes will be tested both in vitro and in vivo on mixtures of SL2 tumor cells seeded into congenic AKR/Cu murine bone marrow. The maximum number of cells that can be eradicated will be determined in a colony assay. Finally, lethally irradiated mice will receive an infusion of treated bone marrow to determine the effect of the drug-containing antibody-directed SPA-liposomes on hematologic reconstitution and efficacy for elimination of leukemia. This investigation will provide a new strategy for eradication of tumor cells prior to autologous bone marrow transplant in patients who have leukemia. Antibody-directed liposomes offer the advantages of more flexibility in selection of cytotoxic agent, the possibility of multiple antibody targeting and potential utility in post-transplant adjuvant therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA039448-01
Application #
3178437
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1985-06-01
Project End
1988-05-31
Budget Start
1985-06-01
Budget End
1986-05-31
Support Year
1
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Papahadjopoulos, D; Allen, T M; Gabizon, A et al. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88:11460-4
Matthay, K K; Abai, A M; Cobb, S et al. (1989) Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. Cancer Res 49:4879-86
Hege, K M; Daleke, D L; Waldmann, T A et al. (1989) Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia. Blood 74:2043-52
Matthay, K K; Heath, T D; Badger, C C et al. (1986) Antibody-directed liposomes: comparison of various ligands for association, endocytosis, and drug delivery. Cancer Res 46:4904-10